glp-1 drugs review GLP-1-based therapies for diabetes, obesity and beyond New analysis of GLP-1 drugs
Description
Publication bias and poor recording of adverse events, which is common in clinical trials, may however explain such paucity of safety signals
One thing is that, in trials, some of these new medications are increasing the amount of weight loss, but that means higher reward, higher risk, with more side effects, says John Morton, MD, MPH, chief of Yale Medicine Bariatric and Minimally Invasive Surgery and a board-certified obesity medicine specialist
Secondary: cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, heart failure
Nauck, M., Frid, A
